4.6 Article

Children of Depressed Mothers 1 Year After Remission of Maternal Depression: Findings From the STAR*D-Child Study

Journal

AMERICAN JOURNAL OF PSYCHIATRY
Volume 168, Issue 6, Pages 593-602

Publisher

AMER PSYCHIATRIC PUBLISHING, INC
DOI: 10.1176/appi.ajp.2010.10010032

Keywords

-

Categories

Funding

  1. NIMH [R01M H063852, N01 MH90003, K02 M H66249]
  2. NIDA
  3. CDC
  4. Aspect Medical Systems
  5. Eli Lilly
  6. PamLab
  7. Pfizer
  8. Agency for Healthcare Research and Quality (AHRQ)
  9. Corcept Therapeutics
  10. Cyberonics
  11. Merck
  12. National Institute on Drug Abuse
  13. Novartis
  14. Pharmacia Upjohn
  15. Predix EPIX Pharmaceuticals
  16. Solvay Pharmaceuticals
  17. Targacept
  18. Abbott Laboratories
  19. Abdi Ibrahim
  20. Akzo (Organon Pharmaceuticals)
  21. AstraZeneca
  22. Bristol-Myers Squibb
  23. Cephalon, Evotec
  24. Fabre Kramer Pharmaceuticals
  25. Forest Pharmaceuticals
  26. GlaxoSmithKline
  27. Janssen Pharmaceutica Products
  28. Johnson Johnson PRD
  29. Meade Johnson
  30. Medtronic
  31. Neuronetics
  32. Otsuka Pharmaceuticals
  33. Parke-Davis Pharmaceuticals
  34. Sepracor
  35. SHIRE Development
  36. VantagePoint
  37. Wyeth-Ayerst Laboratories
  38. Cephalon
  39. Alkermes
  40. BrainCells
  41. CeNeRx BioPharma
  42. Clinical Trials Solutions
  43. Euthymics Bioscience
  44. i3 Innovus/Ingenix
  45. Lorex Pharmaceuticals
  46. Pharmavite
  47. Roche
  48. RCT Logic
  49. Sanofi-Aventis US
  50. Synthelabo
  51. BioResearch
  52. Clintara
  53. Covidien
  54. EnVivo Pharmaceuticals
  55. Ganeden Biotech
  56. Icon Clinical ResearchLichtwer Pharma GmbH
  57. NARSAD
  58. NCCAM
  59. Photothera
  60. Shire
  61. Affectis Pharmaceuticals AG
  62. Amarin Pharma
  63. Auspex Pharmaceuticals
  64. Bayer AG
  65. Best Practice Project Management
  66. BioMarin Pharmaceuticals
  67. Biovail Corporation
  68. CNS Response
  69. Compellis Pharmaceuticals
  70. Cypress Pharmaceutical
  71. DiagnoSearch Life Sciences
  72. Dinippon Sumitomo Pharma
  73. Dov Pharmaceuticals
  74. Edgemont Pharmaceuticals
  75. Eisai Inc.
  76. ePharmaSolutions
  77. EPIX Pharmaceuticals
  78. Fabre-Kramer Pharmaceuticals
  79. GenOmind
  80. Grunenthal GmbH
  81. Janssen Pharmaceutica
  82. Jazz Pharmaceuticals
  83. Knoll Pharmaceuticals
  84. Labopharm
  85. Lundbeck
  86. MedAvante
  87. MSI Methylation Sciences
  88. Naurex
  89. NextWave Pharmaceuticals
  90. Nutrition 21
  91. Orexigen Therapeutics
  92. PharmaStar
  93. PharmoRx Therapeutics
  94. Precision Human Biolaboratory
  95. Prexa Pharmaceuticals
  96. Puretech Ventures
  97. PsychoGenics
  98. Psylin Neurosciences
  99. Rexahn Pharmaceuticals
  100. Ridge Diagnostics
  101. Servier Laboratories
  102. Schering-Plough Corporation
  103. Somaxon Pharmaceuticals
  104. Somerset Pharmaceuticals
  105. Sunovion Pharmaceuticals
  106. Takeda Pharmaceutical Company Limited
  107. Tal Medical
  108. Tetragenex Pharmaceuticals
  109. TransForm Pharmaceuticals
  110. Transcept Pharmaceuticals
  111. Vanda Pharmaceuticals
  112. Adamed
  113. Advanced Meeting Partners
  114. American Psychiatric Association
  115. American Society of Clinical Psychopharmacology
  116. Belvoir Media Group
  117. Boehringer Ingelheim GmbH
  118. CME Institute/Physicians Postgraduate Press
  119. Imedex
  120. MGH Psychiatry Academy/Primedia
  121. MGH Psychiatry Academy/Reed Elsevier
  122. United BioSource
  123. Advanced Neuromodulation Systems
  124. Brain Resource
  125. Bristol-Myers Squibb/Otsuka
  126. Gerson Lehrman Group
  127. Magellan Health Services
  128. Merck Company
  129. Novartis Pharmaceuticals
  130. Ono Pharmaceuticals
  131. Organon
  132. University of Michigan
  133. Urban Institute
  134. Wyeth Ayerst
  135. Forest Laboratories
  136. Otsuka
  137. Stanley Medical Research Institute
  138. ImaRx Therapeutics
  139. Bristol-Myers Squibb Company
  140. Case-Western University
  141. Singapore Clinical Research Institute
  142. Dey Pharmaceuticals
  143. Venebio
  144. Dey

Ask authors/readers for more resources

Objective: Maternal major depressive disorder is an established risk factor for child psychopathology. The authors previously reported that 1 year after initiation of treatment for maternal depression, children of mothers whose depression remitted had significantly improved functioning and psychiatric symptoms. This study extends these findings by examining changes in psychiatric symptoms, behavioral problems, and functioning among children of depressed mothers during the first year after the mothers' remission from depression. Method: Children were assessed at baseline and at 3-month intervals with the Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version, the Child Behavior Checklist, and the Children's Global Assessment Scale for 1 year after their mothers' remission or for 2 years if the mothers did not remit. The authors compared children of early remitters (0-3 months; N=36), late remitters (3-12 months; N=28), and nonremitters (N=16). Results: During the postremission year, children of early-remitting mothers showed significant improvement on all outcomes. Externalizing behavioral problems decreased in children of early-and late-remitting mothers but increased in children of nonremitting mothers. Psychiatric symptoms decreased significantly only in children of mothers who remitted, and functioning improved only in children of early-remitting mothers. Conclusions: Remission of mothers' depression, regardless of its timing, appears to be related to decreases in problem behaviors and symptoms in their children over the year after remission. The favorable effect of mothers' remission on children's functioning was observed only in children of early-remitting mothers.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available